Formulation, optimization, and in vitro evaluation of anastrozole-loaded nanostructured lipid carriers for improved anticancer activity

Design of quetiapine fumarate loaded polyethylene glycol decorated graphene oxide nanosheets: Invitro-exvivo characterization

Quetiapine Fumarate (QF) is an atypical antipsychotic with poor oral bioavailability (9%) due to its low permeability and pH-dependent solubility. Therefore, this study aims to design QF-loaded polyethylene glycol (PEG) functionalized graphene oxide nanosheets (GON) for nasal delivery of QF. In brief, GO was synthesized using a modified Hummers process, followed by ultra-sonication to produce GON. Subsequently, PEG-functionalized GON was prepared using carbodiimide chemistry (PEG-GON). QF was then decorated onto the cage of PEG-GON using the π-π stacking phenomenon (QF@PEG-GON). The QF@PEG-GON nanocomposite underwent several spectral characterizations, in vitro drug release, mucoadhesion study, ex vivo diffusion study, etc. The surface morphology of QF@PEG-GON nanocomposite validates the cracked nature of the nanocomposite, whereas the diffractograms and thermogram of nanocomposite confirm the conversion of QF into an amorphous form with uniform distribution in PEG-GON. Moreover, an ex vivo study of PEG-GON demonstrates superior mucoadhesion capacity due to its surface functional groups and hydrophilicity. The percent drug loading content and percent entrapment efficiency of the nanocomposite were found to be 9.2±0.62% and 92.3±1.02%, respectively. The developed nanocomposite exhibited 43.82±1.65% drug release within 24h, with the Korsemeyer-Peppas model providing the best-fit release kinetics (R2: 0.8614). Here, the interlayer spacing of PEG-GON prevented prompt diffusion of the buffer, leading to a delayed release pattern. In conclusion, the anticipated QF@PEG-GON nanocomposite shows promise as a nanocarrier platform for nasal delivery of QF.

Electrochemical Oxidation of Anastrozole over a BDD Electrode: Role of Operating Parameters and Water Matrix

The electrochemical oxidation (EO) of the breast-cancer drug anastrozole (ANZ) is studied in this work. The role of various operating parameters, such as current density (6.25 and 12.5 mA cm−2), pH (3–10), ANZ concentration (0.5–2 mg L−1), nature of supporting electrolytes, water composition, and water matrix, have been evaluated. ANZ removal of 82.4% was achieved at 1 mg L−1 initial concentration after 90 min of reaction at 6.25 mA cm−2 and 0.1 M Na2SO4. The degradation follows pseudo-first-order kinetics with the apparent rate constant, kapp, equal to 0.022 min−1. The kapp increases with increasing current density and decreasing solution pH. The addition of chloride in the range 0–250 mg L−1 positively affects the removal of ANZ. However, chloride concentrations above 250 mg L−1 have a detrimental effect. The presence of bicarbonate or organic matter has a slightly negative but not significant effect on the process. The EO of ANZ is compared to its degradation by solar photo-Fenton, and a preliminary economic analysis is also performed.